 Connection
Theodore Alkousakis to Humans
This is a "connection" page, showing publications Theodore Alkousakis has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.153 |
|
|
|
-
Browning RJ, Fathi R, Smith MA, Alkousakis T. Flagellate Shiitake Mushroom Reaction With Histologic Features of Acute Generalized Exanthematous Pustulosis. Cutis. 2021 Sep; 108(3):E8-E10.
Score: 0.018
-
Gamboa J, Cameron MC, Fathi R, Alkousakis T. A review of non-pharmacologic approaches to enhance the patient experience in dermatologic surgery. Dermatol Online J. 2020 Mar 15; 26(3).
Score: 0.017
-
Pearson DR, Lewis K, Alkousakis T. Remote-onset alopecia areata attributed to ipilimumab. Cutis. 2019 Dec; 104(6):E25-E27.
Score: 0.016
-
Prince GT, Cameron MC, Fathi R, Alkousakis T. Topical 5-fluorouracil in dermatologic disease. Int J Dermatol. 2018 Oct; 57(10):1259-1264.
Score: 0.015
-
Del Rosario F, Farahi JM, Drendel J, Buntinx-Krieg T, Caravaglio J, Domozych R, Chapman S, Braunberger T, Dellavalle RP, Norris DA, Fathi R, Alkousakis T. Performance of a computer-aided digital dermoscopic image analyzer for melanoma detection in 1,076 pigmented skin lesion biopsies. J Am Acad Dermatol. 2018 05; 78(5):927-934.e6.
Score: 0.015
-
Farahi JM, Fazzari M, Braunberger T, Caravaglio JV, Kretowicz A, Wells K, Dellavalle RP, Norris D, Alkousakis T. Gender differences in melanoma prognostic factors. Dermatol Online J. 2018 Apr 15; 24(4).
Score: 0.015
-
Prince GT, Cameron MC, Fathi R, Alkousakis T. Intralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review. J Drugs Dermatol. 2018 Mar 01; 17(3):274-280.
Score: 0.014
-
Snyder BM, Mounessa JS, Fazzari M, Caravaglio JV, Kretowicz A, Braunberger T, Wells K, Dunnick CA, Dellavalle RP, Alkousakis T. Greater distance to an academic medical center is associated with poorer melanoma prognostic factors: The University of Colorado Experience. Dermatol Online J. 2017 Nov 15; 23(11).
Score: 0.014
-
McMichael A, Shahriari M, Stein Gold L, Alkousakis T, Choi O, Bhutani T, Rodriguez AO, Tyring SK, Chan D, Rowland K, Albrecht L, Lynde C, Yadav G, Yeung J, Park-Wyllie L, Ma T, Jeyarajah J, Gao LL, Smith S, Moore AY, Vashi N, Kindred C, Grimes P, Desai SR, Taylor SC, Alexis A. Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial. JAMA Dermatol. 2025 Sep 01; 161(9):912-922.
Score: 0.006
-
Alexis A, McMichael A, Soung J, Choi O, Alkousakis T, Alonso-Llamazares J, Shahriari M, Rodriguez AO, Bhutani T, Chan D, Rowland K, Sauder M, Hong HC, Yadav G, Yeung J, Jeyarajah J, Ma T, Gao LL, Park-Wyllie L, Green L, Lee M, Vashi N, Kindred C, Grimes P, Taylor SC, Desai SR. Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial. JAMA Dermatol. 2025 Sep 01; 161(9):901-911.
Score: 0.006
-
Alexis A, McMichael A, Vashi N, Bhutani T, Rodriguez AO, Yeung J, Choi O, Chan D, Alkousakis T, Bronner DN, Park-Wyllie L, Gao LL, Grimes P, Shahriari M, Yadav G, Kindred C, Taylor SC, Desai SR. Improving Diversity in a Novel Psoriasis Study: VISIBLE as a Framework for Clinical Trial Quality Improvement. JAMA Dermatol. 2025 Mar 01; 161(3):256-264.
Score: 0.006
-
Snow SC, Pearson DR, Fathi R, Alkousakis T, Winslow CY, Golitz L. Heparin-induced haemorrhagic bullous dermatosis. Clin Exp Dermatol. 2018 Jun; 43(4):393-398.
Score: 0.004
-
Fathi R, Alkousakis T, Brown M. Plaque-Like Atypical Fibroxanthoma, A Rare Invasive Variant. Dermatol Surg. 2017 Jan; 43(1):138-139.
Score: 0.003
-
Hegg RM, Alkousakis TJ, Swick BL. What is your diagnosis? Old world Leishmaniasis. Cutis. 2014 Feb; 93(2):67;69;70.
Score: 0.003
-
Tillou A, Weng J, Alkousakis T, Velmahos G. Fascial dehiscence after trauma laparotomy: a sign of intra-abdominal sepsis. Am Surg. 2003 Nov; 69(11):927-9.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|